Skip to main content
Multiple Myeloma
Teclistamab Showed Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Read More
GC012F, an Autologous BCMA and CD19 Dual-Targeting CAR T-Cell Therapy, as First-Line Treatment for Transplant-Eligible Patients with Newly Diagnosed High-Risk Multiple Myeloma
Read More
Subgroup Analysis of CANDOR-Evaluated Outcomes with Carfilzomib plus Dexamethasone and Daratumumab Based on Cytogenetic Risk
Read More
First Results from a Phase 1 Study of BMS-986393, a GPRC5D-Targeted CAR T-Cell Therapy, in Patients with RRMM
Read More
Subcutaneous Isatuximab Administration by an On-Body Delivery System May Provide a More Convenient Option for Patients with RRMM
Read More
Anti-CD38 Antibodies in the Treatment of RRMM: Considerations for Pharmacists
Read More
Multiple Myeloma
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in High-Risk Multiple Myeloma Patients: Interim Analysis of the GMMG-CONCEPT Trial
Read More
Multiple Myeloma
Evaluating Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review
Read More
Multiple Myeloma
Iberdomide, a Cereblon E3 Ligase Modulator, plus Dexamethasone Demonstrated Activity in Heavily Pretreated Patients with Multiple Myeloma
Read More
Multiple Myeloma
Once-Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: The SKylaRk Trial
Read More
Page 1 of 3
Results 1 - 10 of 25